Evidence map›Paper›PMID 35066757›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway.

B Li, S Pang, J Dou, C Zhou, B Shen, Y Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Clinical Significance ofDiseases (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

B Li *School of Life Science and Technology, China Pharmaceutical University, Jiangsu, 211198, P.R. China.
S Pang *School of Life Science and Technology, China Pharmaceutical University, Jiangsu, 211198, P.R. China.
J DouSchool of Life Science and Technology, China Pharmaceutical University, Jiangsu, 211198, P.R. China.
C ZhouSchool of Life Science and Technology, China Pharmaceutical University, Jiangsu, 211198, P.R. China.
B ShenDepartment of General Surgery, Pancreatic Disease Center, Research Institute of Pancreatic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P.R. China. shenby@shsmu.edu.cn.
Y ZhouDepartment of General Surgery, Pancreatic Disease Center, Research Institute of Pancreatic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P.R. China. zyr12180@rjh.com.cn.ORCID http://orcid.org/0000-0001-6561-7827
China Pharmaceutical University · CNRuijin Hospital · CN

Funding

the Basic Scientific Research Business Expense Project of China Pharmaceutical University No. 2632021ZD07the fellowship of China postdoctoral science foundation 2020T130723the National Key Research and Development Program of China 2018YFA0902000
6 · The paper itself

Abstract

purposeThe long noncoding RNA LINC00261 was reported to be involved in carcinogenesis and has been validated as a tumor suppressor in pancreatic cancer (PC); however, how LINC00261 is regulated has not been fully examined. Here, we attempted to investigate the upstream and downstream targets of LINC00261 in PC.

methodsLINC00261 expression in PC tissues was examined by the Gene Expression Omnibus (GEO) datasets and the Gene Expression Profiling Interactive Analysis (GEPIA) database. The quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays were performed to detect the expression level of LINC00261 in PC cells. The location of LINC00261 in PC cells was identified by RNA fluorescence in situ hybridization (RNA-FISH). Cell Counting Kit-8 (CCK-8), cell apoptosis assay, transwell invasion and migration assays testified the critical role of LINC00261 in PC. The luciferase reporter assay was applied to confirm the binding of LINC00261 to its upstream transcription factor KLF13. The changes in LINC00261 related target protein levels were analyzed by Western blotting assay.

resultsLINC00261 was significantly lower in PC tissues and was mainly concentrated in the nucleus. Overexpression of LINC00261 inhibited the invasion and migration of PC cells. Mechanistically, transcription factor KLF13 was confirmed to inhibit the epithelial-mesenchymal transition (EMT) process of PC cells by promoting the transcription of LINC00261 and suppressing the expression of metastasis-associated proteins, such as matrix metalloproteinase MMP2 and vimentin, thus inhibiting the metastasis of PC.

conclusionLINC00261 regulates PC cell metastasis through the "KLF13-LINC00261-mTOR-P70S6K1-S6" signaling pathway, which provides a significant set of potential PC therapeutic targets.

Indexed as

Kruppel-Like Transcription FactorsMicroRNAsPancreatic NeoplasmsRNA, Long NoncodingCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionHumansIn Situ Hybridization, FluorescenceRepressor ProteinsSignal TransductionTOR Serine-Threonine KinasesTranscription FactorsUp-RegulationCell Cycle ProteinsKLF13 protein, humanKruppel-Like Transcription FactorsMicroRNAsMTOR protein, humanRepressor ProteinsRNA, Long NoncodingTOR Serine-Threonine KinasesTranscription FactorsEMT processKLF13LINC00261Pancreatic cancerTumor metastasis

Identifiers

PMID35066757
OpenAlexW4206944036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.